CL2017003032A1 - Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste - Google Patents

Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste

Info

Publication number
CL2017003032A1
CL2017003032A1 CL2017003032A CL2017003032A CL2017003032A1 CL 2017003032 A1 CL2017003032 A1 CL 2017003032A1 CL 2017003032 A CL2017003032 A CL 2017003032A CL 2017003032 A CL2017003032 A CL 2017003032A CL 2017003032 A1 CL2017003032 A1 CL 2017003032A1
Authority
CL
Chile
Prior art keywords
pharmaceutically acceptable
acceptable salt
pyrido
pyrimidine derivative
pyrimidine
Prior art date
Application number
CL2017003032A
Other languages
English (en)
Inventor
Mizuno Tsuyoshi
Shimada Tomohiro
Unoki Gen
Ebisawa Masaru
Takeuchi Susumu
Minamizono Kunio
Sasaki Kosuke
Yokosaka Takuya
Igarashi Junji
Maruyama Akinobu
Takahashi Hiroshi
HORIE Kyohei
Sakai Yuri
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CL2017003032A1 publication Critical patent/CL2017003032A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>EL PROPÓSITO DE LA PRESENTE INVENCIÓN ES PROPORCIONAR UN COMPUESTO QUE POSEE UNA EXCELENTE ACTIVIDAD INHIBIDORA DE CDK4/6. LA PRESENTE INVENCIÓN ES UN COMPUESTO REPRESENTADO POR LA FÓRMULA (I) O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO.</p>
CL2017003032A 2015-05-29 2017-11-29 Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste CL2017003032A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015110684 2015-05-29

Publications (1)

Publication Number Publication Date
CL2017003032A1 true CL2017003032A1 (es) 2018-03-09

Family

ID=57442335

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003032A CL2017003032A1 (es) 2015-05-29 2017-11-29 Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste

Country Status (29)

Country Link
US (1) US10124004B2 (es)
EP (1) EP3305785B1 (es)
JP (1) JP6400196B2 (es)
KR (1) KR102601320B1 (es)
CN (1) CN107614499B (es)
AR (1) AR104789A1 (es)
AU (1) AU2016272258B2 (es)
CA (1) CA2987019C (es)
CL (1) CL2017003032A1 (es)
CO (1) CO2017012067A2 (es)
CY (1) CY1124800T1 (es)
DK (1) DK3305785T3 (es)
ES (1) ES2893478T3 (es)
HR (1) HRP20211360T1 (es)
HU (1) HUE056996T2 (es)
IL (1) IL255488B (es)
LT (1) LT3305785T (es)
MX (1) MX378648B (es)
MY (1) MY192487A (es)
PH (1) PH12017502171B1 (es)
PL (1) PL3305785T3 (es)
PT (1) PT3305785T (es)
RU (1) RU2695337C2 (es)
SA (1) SA517390409B1 (es)
SG (1) SG11201709837RA (es)
SI (1) SI3305785T1 (es)
TW (1) TWI714590B (es)
WO (1) WO2016194831A1 (es)
ZA (1) ZA201707499B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3546458T1 (sl) 2016-11-28 2021-03-31 Teijin Pharma Limited Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka
MY199852A (en) * 2016-11-28 2023-11-25 Teijin Pharma Ltd Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
CN107337634B (zh) * 2017-08-28 2019-07-09 新发药业有限公司 一种阿贝西利中间体化合物的制备方法
US11299481B2 (en) 2017-10-20 2022-04-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CN111386272B (zh) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
EP3732163A4 (en) 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
MX2020006587A (es) * 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
WO2020125513A1 (zh) 2018-12-19 2020-06-25 凯复制药有限公司 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
AR119493A1 (es) * 2019-07-29 2021-12-22 Servier Lab Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
US12570653B2 (en) * 2020-08-17 2026-03-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Pyrimidine ring compound
GB202018412D0 (en) * 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116023367A (zh) * 2021-10-25 2023-04-28 优领医药科技(香港)有限公司 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用
IL313513A (en) * 2021-12-16 2024-08-01 Teijin Pharma Ltd Cdk9 inhibitor and use thereof
CN116410189B (zh) * 2021-12-30 2024-08-06 中国科学院上海药物研究所 一种嘧啶并吡啶类化合物及其药用组合物和应用
WO2023155841A1 (zh) * 2022-02-16 2023-08-24 南京明德新药研发有限公司 嘧啶并环类化合物的盐型、晶型
EP4514796A4 (en) * 2022-04-25 2026-03-18 Onquality Pharmaceuticals China Ltd CDK INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
TW202417423A (zh) * 2022-07-18 2024-05-01 美商依安彼克醫療有限公司 喹唑啉化合物及使用方法
EP4713096A1 (en) * 2023-05-15 2026-03-25 Aleksia Therapeutics, Inc. Cdk inhibitor compounds
TW202521113A (zh) * 2023-09-27 2025-06-01 日商帝人製藥股份有限公司 類風濕性關節炎治療藥

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
JP4053073B2 (ja) * 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
KR101353857B1 (ko) 2008-08-22 2014-01-21 노파르티스 아게 Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds

Also Published As

Publication number Publication date
CO2017012067A2 (es) 2018-03-28
US20180161329A1 (en) 2018-06-14
NZ737326A (en) 2023-11-24
LT3305785T (lt) 2021-11-10
HRP20211360T1 (hr) 2021-11-26
HK1249502A1 (zh) 2018-11-02
CA2987019C (en) 2023-09-26
WO2016194831A1 (ja) 2016-12-08
TWI714590B (zh) 2021-01-01
IL255488B (en) 2019-12-31
MX378648B (es) 2025-03-11
JPWO2016194831A1 (ja) 2017-12-21
HUE056996T2 (hu) 2022-04-28
DK3305785T3 (da) 2021-10-11
IL255488A (en) 2018-01-31
US10124004B2 (en) 2018-11-13
RU2017141454A3 (es) 2019-05-29
SG11201709837RA (en) 2017-12-28
KR20180011122A (ko) 2018-01-31
CN107614499A (zh) 2018-01-19
CA2987019A1 (en) 2016-12-08
SA517390409B1 (ar) 2021-07-26
CN107614499B (zh) 2020-09-18
SI3305785T1 (sl) 2021-11-30
RU2017141454A (ru) 2019-05-29
BR112017025356A2 (pt) 2018-08-07
PL3305785T3 (pl) 2021-12-27
KR102601320B1 (ko) 2023-11-10
AR104789A1 (es) 2017-08-16
ZA201707499B (en) 2022-09-28
PT3305785T (pt) 2021-10-13
RU2695337C2 (ru) 2019-07-23
AU2016272258A1 (en) 2017-11-30
PH12017502171B1 (en) 2021-07-23
TW201713653A (zh) 2017-04-16
EP3305785A4 (en) 2018-11-21
JP6400196B2 (ja) 2018-10-03
AU2016272258B2 (en) 2020-03-12
MX2017015277A (es) 2018-02-19
PH12017502171A1 (en) 2018-06-04
ES2893478T3 (es) 2022-02-09
EP3305785B1 (en) 2021-08-25
MY192487A (en) 2022-08-23
CY1124800T1 (el) 2022-11-25
EP3305785A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CO2019004034A2 (es) Compuesto de piridina
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2016009230A (es) Macrociclicos con grupos p2&#39;heterociclicos como inhibidores del factor xia.
EA201792021A1 (ru) Ингибитор jak
CL2019001419A1 (es) Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable.
BR112016029825A2 (pt) composto
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
MX381970B (es) Derivado de sulfonamida y composición farmacéutica que contiene el mismo.
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
CL2020000376A1 (es) Compuesto pentacíclico.
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2018000677A (es) Derivado de urea y uso del mismo.